Literature DB >> 32826620

Changing Outdated Methadone Regulations That Harm Pregnant Patients.

John J McCarthy1, Hendree E Jones, Mishka Terplan, Vania P Rudolf, Melinda Campopiano von Klimo.   

Abstract

Methadone regulations have changed minimally since 1974, despite advances in the understanding of the nature of opioid use disorder (OUD) and the role of medications in its treatment. At that time, most patients with OUD were considered to have anti-social personality disorders and the regulations aimed to exert maximal control over medication access. Six- or seven-day clinic attendance is required for months, regardless of distance, or childcare and other social responsibilities. Take home medications are not allowed unless rigid and formulaic conditions are met. Although addiction medicine has rejected the "criminal" paradigm in favor of OUD as a treatable medical disorder, methadone regulations have not kept pace with the science. Pregnancy is characterized by an ultra-rapid metabolic state, but regulations prevent the use of daily divided doses of methadone to maintain stability. This results in repeated episodes of maternal/fetal opioid withdrawal, as well as other fetal physiologic abnormalities. Interference with dose regimen adjustments prevents optimal outcomes. Further, methadone clinics are mostly urban, leaving patients in rural areas without access. This led to excessive morbidity and mortality when the opioid crisis hit. The response of merely expanding capacity in overcrowded urban clinics created a contagion menace when Covid-19 arrived. Pregnant women (and parents with children) were forced to negotiate dosing in dangerous conditions. A revised methadone system must provide treatment that is local, flexible, and limited in size to manage viral contagion risks. This regulatory change can most easily be started by changing regulations that adversely affect pregnant women.
Copyright © 2020 American Society of Addiction Medicine.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32826620      PMCID: PMC8386130          DOI: 10.1097/ADM.0000000000000720

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  10 in total

1.  Fetal stress from methadone withdrawal.

Authors:  F P Zuspan; J A Gumpel; A Mejia-Zelaya; J Madden; R Davis
Journal:  Am J Obstet Gynecol       Date:  1975-05-01       Impact factor: 8.661

2.  A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation.

Authors:  B K Wittmann; S Segal
Journal:  Int J Addict       Date:  1991-02

3.  Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment.

Authors:  Jeffrey H Samet; Michael Botticelli; Monica Bharel
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

4.  Disparities Between US Opioid Overdose Deaths and Treatment Capacity: A Geospatial and Descriptive Analysis.

Authors:  James R Langabeer; Anand Gourishankar; Kimberly A Chambers; Sharmila Giri; Renita Madu; Tiffany Champagne-Langabeer
Journal:  J Addict Med       Date:  2019 Nov/Dec       Impact factor: 3.702

5.  The Use of Serum Methadone/Metabolite Ratios to Monitor Changing Perinatal Pharmacokinetics.

Authors:  John J McCarthy; Ernest J Vasti; Martin H Leamon; Joseph Graas; Coburn Ward; Catherine Fassbender
Journal:  J Addict Med       Date:  2018 May/Jun       Impact factor: 3.702

6.  The effect of methadone dose regimen on neonatal abstinence syndrome.

Authors:  John J McCarthy; Martin H Leamon; Neil H Willits; Ruth Salo
Journal:  J Addict Med       Date:  2015 Mar-Apr       Impact factor: 3.702

7.  Maternal methadone dosing schedule and fetal neurobehaviour.

Authors:  Lauren M Jansson; Janet A Dipietro; Martha Velez; Andrea Elko; Heather Knauer; Katie T Kivlighan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-01

8.  Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods.

Authors:  Amy Chandler; Anne Whittaker; Sarah Cunningham-Burley; Nigel Williams; Kelly McGorm; Gillian Mathews
Journal:  Int J Drug Policy       Date:  2013-05-18

9.  Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.

Authors:  D L Bogen; J M Perel; J C Helsel; B H Hanusa; M Romkes; T Nukui; C R Friedman; K L Wisner
Journal:  Psychopharmacology (Berl)       Date:  2012-08-25       Impact factor: 4.530

10.  Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study.

Authors:  Paul J Joudrey; Nicholas Chadi; Payel Roy; Kenneth L Morford; Paxton Bach; Simeon Kimmel; Emily A Wang; Susan L Calcaterra
Journal:  Drug Alcohol Depend       Date:  2020-03-27       Impact factor: 4.492

  10 in total
  1 in total

1.  Adapting to the Pandemic: Protocol of a Web-Based Perinatal Health Study to Improve Maternal and Infant Outcomes.

Authors:  Golfo Tzilos Wernette; Kristina Countryman; Okeoma Mmeje; Quyen M Ngo; Caron Zlotnick
Journal:  JMIR Res Protoc       Date:  2021-09-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.